Story
KeyCorp Stock Gains After Citi Adds Bank to 'Upside Catalyst Watch' List
Summary
Shares of KeyCorp rose in pre-market trading after Citi designated the regional bank as a near-term bullish pick, a move supported by management's recent confirmation of strong financial targets.
Shares of KeyCorp (NYSE: KEY) climbed 0.6% in pre-open trading after analysts at Citi added the regional bank to its "30-Day Upside Catalyst Watch" list. This designation signals that the investment firm anticipates a significant positive event for the stock in the near future.
Citi's Bullish Stance
Citi's action places KeyCorp in a select group of regional banks with a positive short-term outlook, which also includes U.S. Bancorp and Texas Capital Bancshares, according to the firm's note. The move highlights perceived relative strength, as Citi simultaneously added peer BankUnited to its downside watch list.
The gain in KeyCorp's stock was driven by this company-specific news, as the broader market was largely flat in pre-market activity. The S&P 500, Dow Jones, and Nasdaq all showed minimal movement, indicating no significant macroeconomic tailwind for the banking sector.
Strengthening Fundamentals
AdCiti's tactical endorsement is supported by a strengthening fundamental outlook recently reaffirmed by KeyCorp's management. At a recent investor conference, CFO Clark Khayat confirmed the bank is on track to meet its 2026 financial targets.
Key highlights from the bank's outlook include:
- Commercial loan growth is tracking toward the high end of its 4%–5% target range.
- The bank plans for at least $1.3 billion in share repurchases this year.
- Fee-income growth expectations were raised following the acquisition of Clearwater.
- Management expressed growing confidence in achieving a return on tangible common equity (ROTCE) above 15% by 2027.
Investors are now looking ahead to the company's third-quarter 2026 earnings report, which is scheduled for release on October 20.
Read next
More on Stocks
AI Infrastructure Firm Accelevation Sets IPO Terms, Targeting Up to $5.4 Billion Valuation
AI infrastructure provider Accelevation is targeting a valuation of up to $5.37 billion and aims to raise as much as $720 million in its upcoming U.S. initial public offering, capitalizing on strong investor interest in artificial intelligence.
Quest, Labcorp Shares Tumble on Proposed Medicare Reimbursement Cuts
Shares of Quest Diagnostics and Labcorp fell sharply in premarket trading after the Centers for Medicare & Medicaid Services proposed significant cuts to laboratory testing fees, set to begin in 2027.
Roche's Obesity Drug Enicepatide Shows 15.5% Weight Loss in Mid-Stage Diabetes Trial
Swiss drugmaker Roche announced its experimental obesity drug, enicepatide, helped patients with type 2 diabetes achieve an average 15.5% weight loss and significant blood sugar control in a mid-stage study.
DoorDash to Pay $131.5 Million in NYC Settlement Over Worker Pay Issues
Food delivery giant DoorDash has agreed to a $131.5 million settlement with New York City following a probe that found the company underpaid or delayed payments to its delivery workers.